{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027641","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2026-06-08T12:30:18+00:00","discovered_at":"2026-06-08T12:35:00.347709+00:00","generated_at":"2026-06-08T12:37:37.244069+00:00","sec_items":["1.01","2.03","3.01","3.02","7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vivos Therapeutics enters debt-to-equity exchange; receives Nasdaq bid price deficiency notice","bullets":["Exchange agreement to convert up to $4.5M of Streeterville debt into non-convertible preferred and common stock, contingent on equity financings of at least $2.6M (first tranche) by June 15, 2026.","Streeterville suspends monthly principal redemptions until Sept 15, 2026; reduces monthly cap to $225K; extends note maturity to June 10, 2027.","Vivos issued V-Co Investors 4 LLC a $5M convertible note (initial $500K draw) to support proposed $5.5M equity financing expected by June 30, 2026.","Nasdaq notified Vivos on June 5, 2026, of non-compliance with $1.00 minimum bid price; 180-day cure period ends Dec 2, 2026.","Company also fails Nasdaq's $2.4M minimum stockholders' equity requirement; plans to cure via exchange agreement and equity raise."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027641","json":"https://secwatch.observer/filing/0001493152-26-027641.json","markdown":"https://secwatch.observer/filing/0001493152-26-027641.md","text":"https://secwatch.observer/filing/0001493152-26-027641.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226027641/0001493152-26-027641-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226027641/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T12:37:37.244069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13e9563f39d5e5b38fd01dd86273fbfc733ea064","claim":"Vivos Therapeutics, Inc. incurred convertible notes of maximum principal amount of up to $5,000,000 with V-Co Investors 4 LLC at does not bear any interest.","evidence_excerpt":"On May 7, 2026, the Company entered into an unsecured convertible promissory note in favor of V-Co Investors 4 LLC (“ V-Co 4 ”) in the maximum principal amount of up to $5,000,000","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226027641/0001493152-26-027641-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"maximum principal amount of up to $5,000,000"},{"label":"Counterparty","value":"V-Co Investors 4 LLC"},{"label":"Rate","value":"does not bear any interest"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"20e530806a11063944c9a0136abe62c98cae2640","claim":"Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"June 5, 2026, the Company received a letter from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, from April 23, 2026 to June 4, 2026, the Company is no longer in compliance with the requirement for continued listing on The Nasdaq Capital Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Notice ”). The Notice has no immediate effect on the continued listing status of the Company’s Common Stock on The Nasdaq Capital Market, and, therefore, the Company’s listing remains","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226027641/0001493152-26-027641-index.htm","confidence":0.98,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}